Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blinded, Placebo-controlled Phase III Trial to Evaluate the Efficacy, Safety and Immunogenicity of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) in Adults Aged 18 Years and Older

NCT05398848 is registered in ClinicalTrials.gov with Jiangsu Rec-Biotechnology Co., Ltd. as lead sponsor.

NCT NCT05398848
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05398848 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blinded, Placebo-controlled Phase III Trial to Evaluate the Efficacy, Safety and Immunogenicity of the Recombinant Two-component COVID-19 Vaccine (CHO Cell) in Adults Aged 18 Years and Older
Lead sponsor
Jiangsu Rec-Biotechnology Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2022
Completion date
December 29, 2023
Enrollment
7,623 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19